



Date: August 10, 2024

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 543434

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: SUPRIYA

Dear Sir (s),

Sub: Outcome of Board Meeting in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Saturday, August 10, 2024, inter-alia, has

1. Considered and approved the Unaudited Financial Results for the Quarter ended June 30, 2024
2. Approved the additional Capital Expenditure at Ambemath site for CDMO facility.

The Financials Results will be published in newspapers as required under the Listing Regulations.

The Meeting of the Board of Directors of the Company commenced at 12:30 p.m. and concluded at 02:00 p.m.

Kindly take the above said information on your records.

Thanking you,

Yours faithfully,

For Supriya Lifescience Limited

Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com



SUPRIYA LIFESCIENCE LIMITED

CIN No: L51900MH2008PLC180452


207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063. CIN: L51900MH2008PLC180452

Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

Statement of Standalone Unaudited Financial Results for the Quarter ended June 30, 2024

(₹ In million)

Sr.No.	Particulars	Quarter ended	Quarter ended	Quarter ended	Year ended
		30-06-2024	31-03-2024	30-06-2023	31-03-2024
		Unaudited	Audited	Unaudited	Audited
	Income				
I	Revenue from Operations	1,606.26	1,581.80	1,320.21	5,703.70
II	Other Income	22.24	21.85	29.18	106.35
III	Total Income	1,628.50	1,603.65	1,349.38	5,810.05
2	Expenses				
	a) Cost of Materials Consumed	557.26	483.56	475.28	1,914.30
	b) Purchase of Stock in Trade	-	-	-	-
	c) Change in inventories of finished goods , work in progress & stock in trade.	-71.29	99.05	(3.08)	303.11
	d. Employee benefit expenses	200.84	171.44	154.28	676.38
	e. Finance Cost	3.35	6.01	8.16	21.10
	f. Depreciation & amortisation expense	46.56	39.14	39.55	158.11
	g. Other expenditure	294.03	272.71	248.81	1,080.15
IV	Total Expenses	1,030.76	1,071.90	923.01	4,153.15
V	Profit/(loss) before Exceptional Items & Tax (III -IV)	597.74	531.75	426.38	1,656.90
VI	Exceptional Items	-	-	-	-
VII	Profit/(loss) before Tax (V-VI)	597.74	531.75	426.38	1,656.90
VIII	Tax Expense				
	a) Current Tax	146.67	89.44	99.63	371.00
	b) Deferred Tax	4.64	72.99	41.63	94.76
IX	Profit/(Loss) for the period from Continuing Operations (VII-VII)	446.44	369.32	285.11	1,191.14
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	446.44	369.32	285.11	1,191.14
XIV	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss	(0.74)	0.45	(19.47)	21.69
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	0.19	(0.11)	4.90	(5.46)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)	445.88	369.66	270.55	1,207.37
XVI	Earnings per equity Share (for continuing operation):				
	(1) Basic (In ₹)	5.54	4.59	3.54	14.80
	(2) Diluted (In ₹)	5.54	4.59	3.54	14.80
XVII	Earnings per equity Share (for discontinued operation):				
	(1) Basic (In ₹)	-	-	-	-
	(2) Diluted (In ₹)	-	-	-	-
XVIII	Earnings per equity Share (for discontinued & continuing operations):				
	(1) Basic (In ₹)	5.54	4.59	3.54	14.80
	(2) Diluted (In ₹)	5.54	4.59	3.54	14.80



See accompanying notes to the financial statements:

Notes:-

1. The unaudited Standalone financial results of the Company for the quarter ended June 30, 2024 have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as ammended.
2. The above unaudited standalone financial results of the Company for the quarter ended June 30, 2024 have been reviewed by the Audit Committee on August 10, 2024 and thereafter approved by the Board of Directors at their meeting held on August 10, 2024.
3. The Company has adopted Ind AS 116 "Leases" effective April 01, 2019, using modified retrospective method. The Company has applied the standard to all its leases with the cumulative impact recognized on the date of initial application i.e. April 01, 2019.
4. The figures of the previous periods have been regrouped wherever necessary to conform to the current period presentation.

Place :- Mumbai
Date :- August 10, 2024.



For Supriya Lifescience Limited

Dr. Satish Waman Wagh
Chairman and Whole time director
DIN: 01456982

KAKARIA AND ASSOCIATES LLP

CHARTERED ACCOUNTANTS

UJWAL K. KAKARIA B.Com., B.L., F.C.A.

SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A.

JAIPRAKASH H. SHETHIYA B.Com., F.C.A.


YOUR REF.:

OUR REF.:

Independent Auditor's Review Report on Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
Board of Directors of Supriya Lifescience Limited,

1. We have reviewed the accompanying statement of unaudited financial results of **Supriya Lifescience Limited** ("the Company") for the quarter ended 30th June ,2024, ("the Statement"), being submitted by the company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing regulations")
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been compiled from the related IND AS Financial Statements which has been prepared in accordance with Indian Accounting Standards prescribed under Section 133 of the Companies Act 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants



802, Lotus Trade Centre, Near D.N. Nagar Metro Station, New Link Road, Andheri West,
Mumbai - 400 053 Tel: 022 26744670. Email: mumbai@kakariaassociates.com

Website: www.kakariaassociates.com



of India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 14th October, 2021 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For,
Kakaria and Associates LLP
Chartered Accountants.
FRN: 104558W/ W100601



CA. Ujwal K. Kakaria
Partner
Membership No. – 035416
Place: - Mumbai
Date: - 10th August, 2024
UDIN: - 24035416BKGOSH8929





Date: August 10, 2024

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 543434

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: SUPRIYA

Dear Sir (s),

Sub: Approval of Capital Expenditure at Ambernath site for CDMO facility

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that Company has initially approved a capex program at Ambernath site with an estimated aggregate capital outlay of Rs. 75 crores over the next 3 years.

The Board of Directors, at their meeting held today has additionally approved capital expenditure of approx. Rs. 16 crores for site development and related infrastructure on approx. 5000 sq mtr. of land for project at Ambernath. The said capital expenditure would be majorly funded by the Company out of its internal accruals.

The development of this factory will enable the Company to set up facility required for various CDMO projects.

Kindly take the above said information on your records.

Thanking you,

Yours faithfully,

For Supriya Lifescience Limited

Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com